YARD-FORCE
27.6.2024 19:07:35 CEST | Business Wire | Press release
Yard Force is proud to announce the successful presentation of its latest groundbreaking garden tools and robotic mowers at Spoga Gafa 2024, held in Cologne, Germany, from June 24-26, 2024. The event provided an excellent platform for Yard Force to demonstrate its commitment to innovation and excellence in garden care technology.
Revolutionizing Lawn Care with Yard Force Virtual Boundary Robotic Mowers:
- iVR10: This state-of-the-art model is equipped with Real-Time Kinematic (RTK) technology, Visual Simultaneous Localization and Mapping (VSLAM), and RGB cameras, ensuring pinpoint accuracy and exceptional performance. The 4-wheel drive system and multiple cutting patterns allow the iVR10 to tackle any terrain with ease, delivering a flawless lawn.
- i400: Designed for simplicity and efficiency, the i400 model features an RGB camera that enhances its navigation capabilities, making it an ideal choice for homeowners seeking reliable and consistent lawn maintenance.
- iV6: Combining the advanced navigation of VSLAM with the precision of RGB cameras, the iV6 offers superior maneuverability and cutting performance, adapting effortlessly to various lawn conditions.
Enhanced Performance with Yard Force Riding Mowers and ZTR Models:
Yard Force’s new riding mowers and ZTRs are engineered to provide unparalleled power and efficiency. Featuring ergonomic designs and robust engines, these models ensure smooth operation and exceptional cutting performance, making them perfect for large-scale lawn maintenance tasks.
Innovative 20V x 2 Lawn Mowers with One-Button Cutting Height Adjustment:
The latest range of Yard Force 20V x 2 lawn mowers introduces a revolutionary one-button cutting height adjustment feature. This innovation allows users to effortlessly switch between cutting heights, ensuring precise and tailored lawn care with minimal effort.
High-Pressure Washers for Superior Cleaning:
Yard Force's new high-pressure washers are designed to handle the most demanding cleaning tasks. These powerful tools offer high performance and durability, making them ideal for maintaining outdoor spaces in pristine condition.
A Successful Showcase at Spoga Gafa 2024:
At Spoga Gafa 2024, Yard Force’s booth attracted significant attention from industry professionals, retailers, and garden enthusiasts. The event highlighted Yard Force’s dedication to advancing garden care technology and its ability to meet the evolving needs of consumers.
About Yard Force:
Yard Force is a leading global brand in innovative garden tools and outdoor power equipment. Known for its commitment to quality, performance, and customer satisfaction, Yard Force continuously strives to deliver products that enhance the gardening experience. With a focus on cutting-edge technology and user-friendly designs, Yard Force is dedicated to helping consumers achieve the perfect garden.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627381649/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom